BullFrogAI Releases White Paper on AI in Drug Discovery

BullFrogAI has introduced a new white paper titled "Why Drug Discovery Fails and How AI is Changing the Equation." The document critiques traditional biopharma research and development practices, highlighting that nearly 90% of drug candidates fail in clinical trials. It proposes an AI-driven framework to significantly improve these odds.

Central to this new approach is bfLEAP, BullFrogAI's proprietary platform. The platform is designed to handle the complex biology and high dimensionality involved in drug development. It aims to replace reliance on opaque algorithms and intuition with AI solutions that are biologically grounded, transparent, and based on causality.

The bfLEAP platform spans the entire drug development lifecycle, from early discovery to late-stage trials. It uses causal AI and combinatorial modeling to provide actionable insights, helping biopharma teams predict therapeutic success with greater confidence. This approach is intended to reduce failure rates and accelerate development cycles in the biopharma industry.